Gyro, Their patent does not detect cancer. It is a method of treating cancer using modified AFP. And yes, the fact that they are using modified AFP to treat cancer via RECAF validates RECAF as an indicatior of cancer.
What is does show however, Bocx is not going to be alone in therapeutics using RECAF.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.